Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1340825rdf:typepubmed:Citationlld:pubmed
pubmed-article:1340825lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C0205653lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C0205474lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C0020541lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C0033497lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1340825lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:1340825pubmed:issue3lld:pubmed
pubmed-article:1340825pubmed:dateCreated1993-12-29lld:pubmed
pubmed-article:1340825pubmed:abstractTextAn adequate propranolol dose to reduce 25% the initial heart rate was searched in 19 children with portal hypertension. 13 were pre-hepatic and 6 hepatic hypertension, mean age: 6.96 +/- 3.48 years, range: 2-14 years. Treatment was started with 0.5 mg/kg/day increasing 0.25 mg/kg/day every third day, needing an average of 26 +/- 13 days (range: 6-54 days) to obtain the response. Daily dose ranged from 1 to 5.25 mg/kg/day (mean: 2.69 +/- 1.16). The highest daily dose was 175 mg, the lowest 23.4 mg (mean: 58.27 +/- 36.6 mg/day). Some parameters were evaluated before and after achieving the dose. There was a significant reduction of mean blood pressure (p < 0.01) and peripheral venous pressure (p < 0.05) in 68.4% of patients. A significant elevation (p < 0.001) of 24 hour urinary catecholamine levels occurred in 94.7%. Side effects were minimal. Propranolol could be considered a safe pharmacological option in these patients.lld:pubmed
pubmed-article:1340825pubmed:languagespalld:pubmed
pubmed-article:1340825pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1340825pubmed:citationSubsetIMlld:pubmed
pubmed-article:1340825pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1340825pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1340825pubmed:statusMEDLINElld:pubmed
pubmed-article:1340825pubmed:issn0016-3503lld:pubmed
pubmed-article:1340825pubmed:authorpubmed-author:CastroJJlld:pubmed
pubmed-article:1340825pubmed:authorpubmed-author:CarvajalAAlld:pubmed
pubmed-article:1340825pubmed:authorpubmed-author:KolsterJJlld:pubmed
pubmed-article:1340825pubmed:authorpubmed-author:CallegariCClld:pubmed
pubmed-article:1340825pubmed:authorpubmed-author:de KolsterC...lld:pubmed
pubmed-article:1340825pubmed:authorpubmed-author:Rapa de...lld:pubmed
pubmed-article:1340825pubmed:issnTypePrintlld:pubmed
pubmed-article:1340825pubmed:volume46lld:pubmed
pubmed-article:1340825pubmed:ownerNLMlld:pubmed
pubmed-article:1340825pubmed:authorsCompleteYlld:pubmed
pubmed-article:1340825pubmed:pagination199-207lld:pubmed
pubmed-article:1340825pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:meshHeadingpubmed-meshheading:1340825-...lld:pubmed
pubmed-article:1340825pubmed:articleTitle[Propranolol in children and adolescents with portal hypertension: its dosage and the clinical, cardiovascular and biochemical effects].lld:pubmed
pubmed-article:1340825pubmed:affiliationDepartamento de Pediatría, Universidad de Carabobo, Hospital Central de Valencia.lld:pubmed
pubmed-article:1340825pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1340825pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1340825pubmed:publicationTypeEnglish Abstractlld:pubmed